- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02137252
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial has two phases (a monitoring and an intervention phase).
Monitoring Phase: Prior to starting radiotherapy for non-metastatic breast cancer, participants will be approached and consented for the monitoring phase of the study, which involves longitudinal monitoring of fatigue in order to establish whether a patient develops fatigue after starting radiation. The level of pre-radiotherapy fatigue will be obtained during the final two weeks before radiotherapy is started. All participants will undergo weekly monitoring of fatigue via a brief self-report questionnaire. The monitoring period will continue up until one month after the conclusion of radiotherapy. Those whose fatigue symptoms increase above the pre-specified threshold at any point during the monitoring period will be approached about enrollment into the intervention phase of the study.
Intervention Phase: This is a randomized, double-blind, parallel-arm 5-week clinical trial which will be used to determine the effect of naltrexone on fatigue emerging during radiation therapy for non-metastatic breast cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hosptial
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Eligibility Criteria for Monitoring Phase
- Age ≥ 18
- Diagnosis of: invasive breast cancer (stage I-III), ductal carcinoma in situ, lobular carcinoma in situ, lobular carcinoma
- Plan to receive radiation therapy
Eligibility Criteria for Randomization Phase
- Participants may have had prior breast surgery and/or chemotherapy.
Age ≥18 years.
--Because no dosing or adverse event data are currently available on the use of naltrexone in cancer patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
Participants must have acceptable pre-treatment laboratory values as defined below:
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- If child-bearing potential, willingness to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document
- Receiving radiation therapy of any type at DFCI, BWH, or MGH (including but not limited to partial breast irradiation, two-field, three-field, and four-field plans)
- FACIT-F subscale score >=10 pre-radiation therapy and decrease in FACIT-F of 10 points or more as compared to pre-radiotherapy baseline
Exclusion Criteria:
Exclusion Criteria for Monitoring Phase
- Suicidal ideation, as determined via PHQ-9
- Non-English speaking
Exclusion Criteria for Randomization Phase
- Participants with major depressive disorder and/or suicidal ideation as determined by PHQ-9.
- Participants who are receiving any other investigational agents that might interact with study medication or influence the measurement of study outcomes.
- Participants with known metastatic disease should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to naltrexone.
- Participants who have used opioid-containing medications (including cough/cold medications containing codeine and/or antidiarrheals containing loperamide) in the past 2 weeks, or who are expected to require opioid-containing medications within the duration of the treatment period.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because naltrexone is category C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with naltrexone, breastfeeding should be discontinued if the mother is treated with naltrexone.
- Participants using other contraindicated medications (thioridazine, yohimbine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naltrexone
The treatment schedule includes a daily dose of naltrexone for 5 weeks.
Treatment will be initiated at 25 mg/day during the first week to improve tolerability.
The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
|
Other Names:
|
Placebo Comparator: Sugar Pill
The treatment schedule includes a daily dose of equivalent placebo for 5 weeks.
Treatment will be initiated at 25 mg/day during the first week to improve tolerability.
The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FACIT-fatigue Subscale Score From Randomization to End of Study
Time Frame: Evaluated at baseline, weekly monitoring visits from start of radiation therapy and meets fatigue eligibility threshold
|
Functional Assessment of Chronic Illness Therapy-Fatigue Subscale (FACIT-fatigue subscale): This 13-item self-report scale measuring fatigue and functional impairment as a result of fatigue has been validated in cancer patients (Cella et al.
Cancer 2002;94:528-38) The scale is reverse-scored and the range is 0 (maximum fatigue) - 52 (minimum fatigue).
According to ICD10 criteria, a score <= 34 indicates significant cancer related fatigue.
A change of 10 points has been shown to constitute a clinically meaningful difference on this subscale.
|
Evaluated at baseline, weekly monitoring visits from start of radiation therapy and meets fatigue eligibility threshold
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fremonta Meyer, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma in Situ
- Breast Neoplasms
- Fatigue
- Carcinoma
- Breast Carcinoma In Situ
- Carcinoma, Ductal
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Lobular
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- 14-056
- R01CA150226 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ductal Carcinoma in Situ
-
Yale UniversityPatient-Centered Outcomes Research InstituteCompletedDuctal Carcinoma In SituUnited States
-
Sunnybrook Health Sciences CentreTerminated
-
Windy Hill Medical, Inc.UnknownDuctal Carcinoma In SituUnited States
-
Xoft, Inc.Icad, Inc.WithdrawnDuctal Carcinoma In Situ | Invasive Ductal Carcinoma
-
Duke UniversityWithdrawnBreast Reconstruction | Ductal Carcinoma In-situUnited States
-
Stanford UniversityRecruitingSurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)Ductal Breast Carcinoma in SituUnited States
-
M.D. Anderson Cancer CenterCompletedDuctal Carcinoma In SituUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaboratorsRecruitingPostmenopausal | Ductal Breast Carcinoma In SituUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupActive, not recruitingDuctal Breast Carcinoma In SituUnited States
-
Washington University School of MedicineLifeCellCompletedBreast Cancer | Prophylactic Mastectomy | Ductal Carcinoma in Situ - CategoryUnited States
Clinical Trials on Naltrexone
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Alkermes, Inc.Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Centre for Addiction and Mental HealthUnknown
-
Drug Delivery Company, LLC DBA Akyso PharmaceuticalsNational Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...Not yet recruiting
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States